Inflammatory Bowel Disease Cohort in Nantes

Cohorte Nantaise de Maladies Inflammatoires Chroniques Intestinales

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06256393

Acronym

CELESTE

Enrollment

360

Registered

2024-02-13

Start date

2025-02-04

Completion date

2031-02-28

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

Crohn's disease, Ulcerative colitis, Cohort, Biocollection pathophysiology

Brief summary

The CELESTE cohort will be a three-center prospective cohort associated with the creation of a biobank including Inflammatory Bowel Diseases (IBD) patients with active disease

Detailed description

The CELESTE cohort will be a prospective cohort of IBD patients followed up at Nantes University Hospital, Jules Verne Clinic (Nantes) and/or Confluent Private Hospital (Nantes). The multicentric nature of the cohort including a tertiary referral center and two secondary care centers is a major asset, enabling the enrolment of a broad spectrum of patients, from those naïve to any immunomodulatory treatment to those refractory to multiple biologic therapies. It will be associated with a multi-omics biobank with the aim of identifying new cellular and molecular signatures of success of the therapeutic strategy at one year.

Interventions

OTHERCollection of biological samples

Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age; * Patients with an established diagnosis of IBD: CD, UC, unclassified IBD or refractory chronic pouchitis; * Patients with active disease requiring surgery or endoscopy, whether performed at diagnosis or prior to initiation of new therapy; * Patients who have given written consent to participate in the study and to keep biological samples for research purposes

Exclusion criteria

* Patients refusing to participate in the cohort; * Patients with chronic inflammatory bowel disease quiescent at inclusion; * Patients with a contraindication to general anaesthesia; * Vulnerable patients (under court protection, curators, guardians);

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients who succeed in their therapeutic strategy	One year after inclusion	Determine the proportion of patients who succeed in their therapeutic strategy at one year

Countries

France

Contacts

Primary ContactCatherine Le Berre, MD

catherine.leberre@chu-nantes.fr+33240083152

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026